HWM
HRTX icon

HB Wealth Management’s Heron Therapeutics HRTX Stock Holding History

HB Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.95K Buy
11,189
+888
+9% +$1.03K ﹤0.01% 1544
2025
Q4 		$13.4K Sell
10,301
-1,169
-10% -$1.44K ﹤0.01% 1397
2025
Q3 		$14.5K Buy
11,470
+1,383
+14% +$2.19K ﹤0.01% 1335
2025
Q2 		$20.9K Buy
10,087
+87
+0.9% +$178 ﹤0.01% 1153
2025
Q1 		$22K Hold
10,000
– – ﹤0.01% 1204
2024
Q4 		$15.3K Hold
10,000
– – ﹤0.01% 1067
2024
Q3 		$19.9K Hold
10,000
– – ﹤0.01% 967
2024
Q2 		$35K Buy
+10,000
New +$30.7K ﹤0.01% 913

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

HB Wealth Management's HRTX Position: Q1 2026 in Review

HB Wealth Management increased its Heron Therapeutics (HRTX) stake by 8.6% in Q1 2026, buying an estimated $1.03K and bringing the position to 11,189 shares worth $8.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

HB Wealth Management first reported a position in HRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $35K in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • HB Wealth Management held 11,189 shares of Heron Therapeutics worth $8.95K as of Q1 2026.
  • HB Wealth Management bought 888 Heron Therapeutics shares in Q1 2026, an estimated $1.03K.
  • Heron Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q1 2026, its #1544 holding.
  • HB Wealth Management first reported a position in Heron Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • HB Wealth Management's Heron Therapeutics position peaked at $35K in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on HB Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.